Scholarlink

Background <p>Laryngeal and hypopharyngeal squamous cell carcinomas are among the most common head and neck malignancies, presenting a dual clinical challenge of achieving tumor eradication while preserving laryngeal function. This study evaluated the efficacy and preservation of laryngeal function effects of different neoadjuvant treatment regimens in patients.</p> Methods <p>This retrospective study analyzed data from 110 patients with loco-regionally advanced laryngeal and hypopharyngeal cancer. Patients were categorized into three groups based on the neoadjuvant treatment regimens administered: TP chemotherapy group (albumin-bound paclitaxel plus cisplatin), camrelizumab plus TP chemotherapy group, and cetuximab plus TP chemotherapy group. To make a Kaplan-Meier survival curve plot for 3 groups and do a log-rank test on these groups. We executed receiver operation capability (ROC) curve examination and a multivariate Coxproportional dangers regression to recognize separate prognostic determinants for 2-year overall survival (OS).</p> Results <p>Compared with TP chemotherapy alone, camrelizumab plus TP chemotherapy demonstrated significant improvements in multiple endpoints (all <i>P</i> &lt; 0.05). The objective response rate (ORR) in the camrelizumab plus TP chemotherapy group was 90.0%, the 2-year progression-free survival (PFS) rate was 75.0%, and the 2-year laryngectomy-free survival (LFS) rate was 67.5%. However, the 2-year OS rate was 80.0%, indicating no significant improvement (<i>P</i> &gt; 0.05). The cetuximab plus TP chemotherapy group did not demonstrate significant improvements in any of the above three endpoints (all <i>P</i> &gt; 0.05). No significant difference was observed in the incidence of major adverse events among the three groups (<i>P</i> &gt; 0.05). Cox regression analysis revealed that the systemic immunoinflammatory index (SII), neutrophil-lymphocyte ratio (NLR), and N stage were independent prognostic factors. ROC curve analysis demonstrated that the areas under the curve (AUC) for SII and NLR in predicting prognosis were 0.839 (95% confidence interval [CI]: 0.755–0.923) and 0.853 (95% CI: 0.772–0.934), respectively.</p> Conclusion <p>In patients with loco-regionally advanced laryngeal and hypopharyngeal carcinoma, combining camrelizumab with TP chemotherapy demonstrates favorable short-term efficacy and laryngeal preservation rates while maintaining an acceptable safety profile. The inflammatory immune markers SII and NLR have valuable predictive utility in this patient population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月27日

查看全文
  • Nannan Cai,
  • Haotian Wei,
  • Yiyang Chen,
  • Jia Wang,
  • Penghui Li,
  • Chuncheng Hao

摘要

Background

Laryngeal and hypopharyngeal squamous cell carcinomas are among the most common head and neck malignancies, presenting a dual clinical challenge of achieving tumor eradication while preserving laryngeal function. This study evaluated the efficacy and preservation of laryngeal function effects of different neoadjuvant treatment regimens in patients.

Methods

This retrospective study analyzed data from 110 patients with loco-regionally advanced laryngeal and hypopharyngeal cancer. Patients were categorized into three groups based on the neoadjuvant treatment regimens administered: TP chemotherapy group (albumin-bound paclitaxel plus cisplatin), camrelizumab plus TP chemotherapy group, and cetuximab plus TP chemotherapy group. To make a Kaplan-Meier survival curve plot for 3 groups and do a log-rank test on these groups. We executed receiver operation capability (ROC) curve examination and a multivariate Coxproportional dangers regression to recognize separate prognostic determinants for 2-year overall survival (OS).

Results

Compared with TP chemotherapy alone, camrelizumab plus TP chemotherapy demonstrated significant improvements in multiple endpoints (all P < 0.05). The objective response rate (ORR) in the camrelizumab plus TP chemotherapy group was 90.0%, the 2-year progression-free survival (PFS) rate was 75.0%, and the 2-year laryngectomy-free survival (LFS) rate was 67.5%. However, the 2-year OS rate was 80.0%, indicating no significant improvement (P > 0.05). The cetuximab plus TP chemotherapy group did not demonstrate significant improvements in any of the above three endpoints (all P > 0.05). No significant difference was observed in the incidence of major adverse events among the three groups (P > 0.05). Cox regression analysis revealed that the systemic immunoinflammatory index (SII), neutrophil-lymphocyte ratio (NLR), and N stage were independent prognostic factors. ROC curve analysis demonstrated that the areas under the curve (AUC) for SII and NLR in predicting prognosis were 0.839 (95% confidence interval [CI]: 0.755–0.923) and 0.853 (95% CI: 0.772–0.934), respectively.

Conclusion

In patients with loco-regionally advanced laryngeal and hypopharyngeal carcinoma, combining camrelizumab with TP chemotherapy demonstrates favorable short-term efficacy and laryngeal preservation rates while maintaining an acceptable safety profile. The inflammatory immune markers SII and NLR have valuable predictive utility in this patient population.